VEO Ophthalmics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VEO Ophthalmics is a private, commercial-stage medical device company specializing in ophthalmic surgical tools. The company achieved a significant regulatory milestone with the FDA's first Breakthrough Device designation and approval for its CUSTOM FLEX® Artificial Iris, addressing iris defects. With a second commercial product, PLEXITOME™, for corneal conditions, VEO operates in a high-value niche, leveraging direct surgeon feedback to drive innovation and commercial execution in the ophthalmology market.

Ophthalmology

Technology Platform

Focused design and manufacturing of specialized mechanical and implantable devices for anterior segment ophthalmic surgery, including custom silicone implants and precision micro-puncture tools.

Opportunities

The first FDA-approved artificial iris creates a monopoly in a high-need niche market, allowing for premium pricing and establishing the company as an innovator.

The PLEXITOME™ device addresses a larger, common condition (RCE) with a potentially superior mechanical solution, representing a scalable growth opportunity within standard corneal practice.

Risk Factors

The company's revenue is heavily reliant on one flagship product for a very small patient population, creating significant concentration risk.

Competition from alternative surgical techniques or future technological advancements, particularly in the corneal space, could rapidly erode market share for its devices.

Competitive Landscape

For the artificial iris, VEO faces minimal direct competition due to its first-mover FDA approval, though cosmetic contact lenses and older surgical techniques remain alternatives. In the corneal treatment space, PLEXITOME™ competes with manual needle-based stromal puncture, diamond burr polishing, and emerging laser therapies (e.g., phototherapeutic keratectomy), making differentiation on precision and outcomes critical.

More companies in Drug Delivery & Formulation →More companies in United States →